David L. Dawson

TL;DR: In this paper, the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication was evaluated in a prospective, randomized, placebo-controlled, parallel-group clinical trial.

TL;DR: Cilostazol was significantly better than pentoxifylline or placebo for increasing walking distances in patients with intermittent claudication, but was associated with a greater frequency of minor side effects.

TL;DR: Compared with placebo, long-term use of cilostazol, 100 mg or 50 mg, twice a day significantly improves walking distances in patients with intermittent claudication, which is a common manifestation of arterial occlusive disease.

TL;DR: In this paper, the authors examined the impact of the COVID-19 pandemic on psychological health and well-being in the UK during a period of "lockdown" (15th-21st May 2020).

TL;DR: In this paper, the authors describe the development of a new general measure of ACT processes (the CompACT) and explore the measure's factor structure, validity, and reliability, showing good internal consistency, and converged and diverged in theory-consistent ways with other measured variables: higher levels of psychological inflexibility were associated with higher level of distress and lower levels of health and wellbeing.